Bard Associates Inc. Makes New $2.91 Million Investment in U.S. Physical Therapy, Inc. $USPH

Key Points

• Bard Associates acquired 42,368 shares of U.S. Physical Therapy in the second quarter, worth approximately $2.91 million and representing a 0.28% stake. Several other institutional investors, including BlackRock, also initiated positions.
• U.S. Physical Therapy reported quarterly revenue of $214.06 million, up 8.5% year over year and above estimates, but EPS of $0.75 missed consensus by $0.06. Shares recently traded at $78.16, while analysts maintain a “Moderate Buy” consensus with a $99.50 average price target.
• The company declared a quarterly dividend of $0.46 per share, or $1.84 annualized, yielding about 2.4%. However, its reported payout ratio is exceptionally high at 1,082.35%.

Bard Associates Inc. acquired a new position in U.S. Physical Therapy, Inc. (NYSE:USPH - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 42,368 shares of the company's stock, valued at approximately $2,910,000. Bard Associates Inc. owned 0.28% of U.S. Physical Therapy at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Callan Family Office LLC bought a new position in U.S. Physical Therapy in the second quarter worth approximately $1,862,000. BlackRock Inc. bought a new position in U.S. Physical Therapy in the second quarter worth about $155,505,000. Deutsche Bank AG bought a new position in U.S. Physical Therapy in the second quarter worth about $1,119,000. Rice Hall James & Associates LLC purchased a new stake in shares of U.S. Physical Therapy during the second quarter valued at about $1,279,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of U.S. Physical Therapy during the second quarter valued at about $30,000.

U.S. Physical Therapy Trading Up 0.2%

Shares of USPH opened at $78.16 on Friday. U.S. Physical Therapy, Inc. has a 12-month low of $58.19 and a 12-month high of $93.50. The firm has a market capitalization of $1.17 billion, a P/E ratio of 459.79, a P/E/G ratio of 2.15 and a beta of 1.13. The firm has a 50-day moving average price of $73.59 and a 200 day moving average price of $73.90. The company has a current ratio of 1.27, a quick ratio of 1.27 and a debt-to-equity ratio of 0.48.

U.S. Physical Therapy (NYSE:USPH - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.81 by ($0.06). U.S. Physical Therapy had a net margin of 3.97% and a return on equity of 9.39%. The company had revenue of $214.06 million during the quarter, compared to analysts' expectations of $211.36 million. During the same period last year, the firm posted $0.81 earnings per share. U.S. Physical Therapy's revenue was up 8.5% on a year-over-year basis. Sell-side analysts forecast that U.S. Physical Therapy, Inc. will post 2.95 EPS for the current year.

U.S. Physical Therapy Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Friday, August 21st. U.S. Physical Therapy's payout ratio is currently 1,082.35%.

Analyst Ratings Changes

USPH has been the subject of a number of recent analyst reports. Zacks Research raised U.S. Physical Therapy from a "strong sell" rating to a "hold" rating in a research report on Wednesday, May 27th. Weiss Ratings restated a "hold (c-)" rating on shares of U.S. Physical Therapy in a research note on Friday, May 29th. Citizens Jmp reiterated a "market outperform" rating and issued a $98.00 price target on shares of U.S. Physical Therapy in a research note on Wednesday, June 24th. Barrington Research boosted their price target on U.S. Physical Therapy from $90.00 to $98.00 and gave the stock an "outperform" rating in a research note on Monday, August 10th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of U.S. Physical Therapy in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, U.S. Physical Therapy presently has an average rating of "Moderate Buy" and an average price target of $99.50.

Insider Buying and Selling at U.S. Physical Therapy

In related news, Director Peter Francis Minan purchased 492 shares of U.S. Physical Therapy stock in a transaction that occurred on Monday, June 8th. The stock was purchased at an average cost of $63.14 per share, with a total value of $31,064.88. Following the completion of the transaction, the director directly owned 2,923 shares in the company, valued at approximately $184,558.22. The trade was a 20.24% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.40% of the company's stock.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc NYSE: USPH is a leading owner and operator of outpatient physical therapy clinics across the United States. The company delivers rehabilitative care to patients recovering from orthopedic injuries, neurological disorders and chronic conditions. Its core services include one-on-one physical therapy sessions, aquatic therapy, occupational therapy, massage therapy and sports medicine programs designed to restore mobility and enhance quality of life.

In addition to traditional rehabilitation services, U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source